If they take the same care with anti-viral phase trials as they do with nuclear reactors, it is not surprising that the US would want to spend $250+ for there own western trials of lani.
But, one gigantic trial is happening right now ..... the actual general use of lani in Japan. Perhaps the FDA would consider, under these specific circumstances, allowing direct progress to phase 3. We could be reasonably sure that such a proposal has been submitted by Biota. If a 3rd party is providing non dilutive funding, the cost is not important, but the sooner we get to phase 3, the sooner lani will be in the market, and the longer the market will be within the patent period.
PS. I am not anti Japanese.
BTA Price at posting:
97.5¢ Sentiment: None Disclosure: Held
